Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal

INTRODUCTION: In Nepal, adalimumab is the most common agent being used, but in a disease activity-based dose tapering to address the economic constraints. Another constraint is the high risk of reactivation of tuberculosis in countries with high burden, especially with the use of tumor necrosis fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaidya, Binit, Nakarmi, Shweta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463559/
https://www.ncbi.nlm.nih.gov/pubmed/31057626
http://dx.doi.org/10.1155/2019/2034950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463559/
https://www.ncbi.nlm.nih.gov/pubmed/31057626
http://dx.doi.org/10.1155/2019/2034950

Ejemplares similares